Quality of Life for Patients With Breast Cancer Brain Metastases and Leptomeningeal Disease

Part of paid clinical trials in San Francisco, California.

Sponsor
University of California, San Francisco
Study ID
NCT07659652
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Brain Metastases From Breast Cancer
  • Breast Cancer, Metastatic
  • Breast Cancer, Metastatic Breast Cancer
  • Breast Cancer, Quality of Life
  • Leptomeningeal Metastasis of Breast Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Health-Related Quality of Life (QOL) questionnaires — OTHER
    Participants can complete questionnaires online, via tablet in clinic, or via paper and pencil in clinic
  • Medical Chart Review — OTHER
    Data will be collected from the participants electronic medical record

Study Details

Central nervous system (CNS) metastases including breast cancer brain metastases (BCBMs) and leptomeningeal disease (LMD) are common affecting up to 30% of patients with metastatic breast cancer (MBC). The goal of this research is to understand symptom burden and quality of life trajectories in this population and how treatments guide care management decisions.

Key Dates

Start date
Jun 15, 2026
Status verified
Jun 2026
Primary completion
Dec 31, 2030
Completion
Dec 31, 2035

Study Design

Enrollment
200 participants (estimated)

Arms

  • Arm: Participants with Metastatic Breast Cancer
    This is a prospective cohort study of patients with Stage 4 (metastatic) breast cancer with brain metastases and/or leptomeningeal disease who are receiving treatment for cancer or cancer-related disease. Through a series of surveys, participants will be asked about race/menopausal status, social determinants, symptom experience, and cognitive and physical functioning. Participants will be asked to update surveys every 3 months. Additional demographic and on-investigational / routine care treatment information will be obtained from the Electronic Medical Record (EMR).

Primary Outcome Measure

Overall changes in reported symptom burden [ Time Frame: Every 3 months for up to approximately 5 years. ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of California, San FranciscoSan FranciscoCalifornia94143
Amy Langdon
[email protected]
877-827-3222
[email protected]
Laura Huppert, MD (PRINCIPAL_INVESTIGATOR)
Michelle Melisko, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in San Francisco, CA

By research site
University of California, San Francisco· San Francisco, CA

Related Studies